Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
January 26, 2018
Verastem (VSTM) presents pre-clinical data of Duvelisib in combination with co-stimulatory antibodies in a B Cell Lymphoma Model
January 24, 2018
Spark Therapeutics (ONCE) and Novartis (NVS) enter into a Licensing/Supply Agreement with upfront fee of $105 M
January 9, 2018
Histogenics Corporation (HSGX), Receipt of $10 Million Up-front Payment for Japanese Neocart Agreement
January 5, 2018
Takeda Pharmaceutical intents to acquire TiGenix (Brussels and NASDAQ: TIG)
January 3, 2018
Sangamo Therapeutics (SGMO) $12 million collaboration with Pfizer (PFE) on a gene therapy for two neuro-degenerative disorders
January 2, 2018
Vericel Corporation (VCEL initiated a License Agreement with Innovative Cellular Therapeutics (ICT)
December 22, 2017
Biostage (BSTG) the swindle scheme continues with a 1-for-20 reverse split ratio effective 12/22/17
December 18, 2017
Biostage (BSTG): Ponzi or Pyramid scheme or a combination of both …?
December 14, 2017
Biostage (BSTG) raised $4 M with sale of 60 M shares with 100% warrant coverage
December 7, 2017
Biostage (BSTG) de-listing determination
December 6, 2017
Biostage (BSTG) the end is in sight with a lab liquidation auction, next the lights get turned off
November 28, 2017
Cesca Therapeutics (KOOL) proposes 900 K share offering priced at $3.00
November 16, 2017
AxoGen (AXGN) Prices offering of 2 M share at $21.00
November 14, 2017
Regenerative Medicine Earnings Scorecard - Q3/2017 to date
October 30, 2017
Pluristem (PSTI) proposes 8.87 M share offering with different pricing on Tel Aviv Stock exchange (TASE)
October 6, 2017
Biostage (BSTG) Breech, breech … breech
September 20, 2017
Juno Therapeutics (JUNO) proposes $225 M follow-on offering
August 31, 2017
VistaGen (VTGN) prices 1.37 M share offering at $1.75 with 1.89 M warrants attached
June 27, 2017
Histogenics (HSGX) P3 Clinical Trial of Neocart® enrollment completed to Treat Knee Cartilage Damage - BUY
June 26, 2017
bluebird bio (BLUE) prices $350 M share offering at $105.00
June 20, 2017
Sangamo Therapeutics (SGMO) proposes $72.5 M offering
June 12, 2017
Fibrocell Science (FCSC) gets “Rare Pediatric Disease Designation” from FDA
June 1, 2017
Biostage (BSTG) disclosure of material information re a wrongful death complaint
May 31, 2017
Cytori (CYTX) executes $13.4 M Option for burn clinical trial with BARDA
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.